Loading patent…
AssigneeChong Kun Dang Pharmaceutical Corp.
InventorsJaeeun Kim, Jaemin Lee, Dong Hyuk Nam, So Hyun Park, Sung Kwon Kang, Shin Jung Park
Estimating the term…
The present invention relates to donepezil ether palmitate hydrochloride (DEP HCl) and a method for preparing same. Donepezil ether palmitate hydrochloride (DEP HCl) has been developed to have increased stability by suppressing generation of unknown related substances generated during a preparation process of a raw material and formulation of donepezil ether palmitate (DEP). In addition, the present invention relates to a sustained-release pharmaceutical composition comprising donepezil ether palmitate hydrochloride (DEP HCl) as a main ingredient. When administered in the body, the initial release of donepezil, which is an active ingredient, is reduced, thereby reducing the risk of side effects such as drug toxicity, and the constant release of donepezil in the body for a long period of time can improve the drug treatment effect on dementia patients.
An acid addition salt of a compound represented by the following Chemical Formula 3:
2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride represented by the following Chemical Formula 4:
A sustained-release pharmaceutical composition comprising a compound represented by the following Chemical Formula 3:
A sustained-release pharmaceutical composition comprising 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride represented by the following Chemical Formula 4:
A method for preparing an acid addition salt of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate, the method comprising reacting 2-((1-benzylpiperidin-4-yles)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate and acid.
Dependencies are inferred from the claim text.